Medical News

RSS

Pharmacyclics reports total GAAP revenues of $2.1 million for third-quarter fiscal 2010

Pharmacyclics, Inc. today reported financial results for its third quarter ended March 31, 2010.

6 May 2010

Officials in 25 states probe American Trade Association insurance

The Fiscal Times: "Authorities in over 25 states are investigating [the] insurance company, American Trade Association (ATA), and have uncovered what they believe is a deep well of scams that ensnared an estimated 12,000 people who paid about $14 million in premiums. ATA and its lawyer did not respond to repeated requests from The Fiscal Times for comment.

6 May 2010

Whole body MRI helps physicians diagnose and treat breast cancer: Study

Whole body magnetic resonance imaging should be the imaging modality of choice for the detection of breast cancer metastases (when the cancer has spread beyond the breast) as it is highly accurate and can detect bone metastases while a patient is still asymptomatic (shows no symptoms), according to a study to be presented at the ARRS 2010 Annual Meeting in San Diego, CA.

6 May 2010

Caffeine is effective in preventing cataract formation, says study

Caffeine may be effective in protecting the lens against damage that could lead to the formation of cataracts, according to a study presented on May 4 at the 2010 Annual Meeting of the Association for Research in Vision and Ophthalmology.

6 May 2010

Watson Laboratories files raloxifene hydrochloride tablet ANDA

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc. filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market a raloxifene hydrochloride tablet. Watson's raloxifene hydrochloride tablet is a generic version of Eli Lilly's EVISTA®.

6 May 2010

Positive results from Phase IIa clinical study of LIPO-102

Lithera, Inc. today announced positive results from a Phase IIa clinical study of LIPO-102, its novel injectable combination of salmeterol xinafoate and fluticasone propionate for selective, non-ablative fat reduction. LIPO-102 was well-tolerated when administered weekly for 8 weeks into the subcutaneous abdominal fat of healthy subjects.

6 May 2010

New HR Compliance solution simplifies healthcare database

HighRoads, an industry leader in employer health care database and benefits management, today announced the launch of HR Compliance™, a new solution designed to simplify and automate the creation and update of Medical Summary Plan Descriptions (SPDs) so that they comply with new health care reform language.

6 May 2010

ImmunoGen proposes underwritten common stock public offering

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, announced today that it intends to offer, subject to market and other conditions, 8,500,000 shares of its common stock in an underwritten public offering. ImmunoGen expects to grant the underwriters a thirty (30) day option to purchase up to 1,275,000 additional shares to cover over-allotments, if any.

6 May 2010

Omega Healthcare Investors reports $21.0 million net income for first-quarter 2010

Omega Healthcare Investors, Inc. today announced its results of operations for the quarter ended March 31, 2010. The Company also reported Funds From Operations ("FFO") available to common stockholders for the three months ended March 31, 2010 of $33.4 million or $0.38 per common share.

6 May 2010

Innate Therapeutics receives funding to conduct Phase 2A clinical trial for MIS416

Innate Therapeutics today announced funding support from Fast Forward, LLC, a not-for-profit organization established by the U.S. National Multiple Sclerosis Society and EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany. The award of funds will help support the conduct of a Phase 2A clinical trial in patients with progressive forms of MS using MIS416, a naturally occurring agent derived from bacteria.

6 May 2010

Jazz Pharmaceuticals reports 59% increase in first-quarter 2010 revenue

Jazz Pharmaceuticals, Inc. announced financial results for the first quarter ended March 31, 2010 and updated guidance for sales and expenses for 2010.

6 May 2010

Early extension of health insurance for some young adults faces legal roadblocks

The Associated Press reports, in a Q & A, that the provision in the health reform law that requires insurers to allow dependents to stay on plans up to the age of 26 is being enacted early by many health insurance companies but not all in the same way. "These voluntary extensions come with a host of qualifications. Whether your child gets one also can depend on your employer."

6 May 2010

Officials investigate if use of surgical robot led to injuries

The Wall Street Journal: Injuries at a small New Hampshire hospital that uses a surgical robot have some questioning the use of such machines in the care of people. The machine, which is named after Leonardo da Vinci, has been linked to surgeries where patients have been hurt, including two with lacerated bladders and one woman who required four subsequent surgeries after errors using the machine.

6 May 2010

Endo Pharmaceuticals to acquire all outstanding shares of HealthTronics common stock

HealthTronics, Inc., a leading provider of urological products and services, today announced that it has signed a definitive merger agreement with Endo Pharmaceuticals pursuant to which Endo will acquire HealthTronics.

6 May 2010

Emergent Biosolutions reports decreased revenue in 2010 first quarter

Emergent BioSolutions Inc. announced today its financial results for the first quarter ended March 31, 2010. For the first quarter 2010, total revenues were $46.8 million as compared to $64.5 million in 2009, and net income was $2.5 million, or $0.08 per share, as compared to $11.1 million, or $0.37 per share, in 2009.

6 May 2010

Novocell is now ViaCyte

Novocell, Inc., a preclinical stage stem cell engineering company focused on diabetes, announced today the Company's shareholders and Board of Directors approved a name change to ViaCyte, Inc.

6 May 2010

GeoVax Labs reports net loss of $690,789 for first-quarter 2010

GeoVax Labs, Inc., a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, today announced its financial results for the three months ended March 31, 2010.

6 May 2010

Forward's second-quarter gross profit up 50%

Forward Industries, Inc., a designer and distributor of custom carrying case solutions, today announced financial results for its second fiscal quarter ended March 31, 2010.

6 May 2010

Use of combined PET/CT can confirm suspected colorectal cancer recurrence at early stage: Study

The use of combined positron emission tomography and computed tomography can confirm a suspected colorectal cancer recurrence at an early stage, helping significantly in treatment planning and improved targeted patient care, according to a study to be presented at the ARRS 2010 Annual Meeting in San Diego, CA.

6 May 2010

GOP's 'repeal health law' strategy may backfire in general election

Politico reports that several goals of Republicans -- including the repeal of the health care law -- "put them at odds with the majority of voters, according to a new survey by Resurgent Republic," a nonprofit polling and research group established by "GOP operative" Ed Gillespie to assist conservatives and Republicans.

6 May 2010